{"schema_version":"secwatch.filing_event.v1","accession":"0000875320-26-000171","form_type":"8-K","ticker":"VRTX","cik":"0000875320","company_name":"VERTEX PHARMACEUTICALS INC / MA","filed_at":"2026-05-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.846374+00:00","generated_at":"2026-05-15T00:10:27.579770+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Vertex Q1 revenue $2.99B (+8% YoY); reiterates FY2026 guidance; povetacicept BLA submitted for accelerated approval","bullets":["Total revenue $2.99B, up 8% vs Q1 2025; GAAP net income $1.0B, non-GAAP $1.1B.","CASGEVY revenue $43M; JOURNAVX revenue $29M; non-CF products drove >25% of growth.","Completed rolling BLA submission for povetacicept in IgAN for U.S. accelerated approval; Priority Review Voucher expected to expedite review to 6 months.","Terminated VX-522 (CF) Phase 1/2 due to persistent tolerability issues; no efficacy readout possible.","FY2026 guidance reiterated: revenue $12.95-13.1B, combined R&D/SG&A unchanged."],"urls":{"canonical":"https://secwatch.observer/filing/0000875320-26-000171","json":"https://secwatch.observer/filing/0000875320-26-000171.json","markdown":"https://secwatch.observer/filing/0000875320-26-000171.md","text":"https://secwatch.observer/filing/0000875320-26-000171.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000171/0000875320-26-000171-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000171/vrtx-20260504.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T00:10:27.579770+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"44109f8b69cc01c7b5d67b47df97f08411c8dd7c","claim":"VERTEX PHARMACEUTICALS INC / MA reported Q1 2026 results: revenue $2.99 billion, net income $1.0 billion.","evidence_excerpt":"Vertex Reports First Quarter 2026 Financial Results — Total revenue of $2.99 billion, an 8% increase compared to first quarter 2025 —","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000171/0000875320-26-000171-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Q1 2026"},{"label":"Revenue","value":"$2.99 billion"},{"label":"Net income","value":"$1.0 billion"},{"label":"Result","value":"reported results"}]},{"claim_id":"44109f8b69cc01c7b5d67b47df97f08411c8dd7c","claim":"VERTEX PHARMACEUTICALS INC / MA reported Q1 2026 results: revenue $2.99 billion, net income $1.0 billion.","evidence_excerpt":"except as shall be expressly set forth by specific reference in such filing. --- EX-99.1 (EX-99.1) --- Vertex Reports First Quarter 2026 Financial Results — Total revenue of $2.99 billion, an 8% increase compared to first quarter 2025 — — Povetacicept program continues rapid advancement: Completed rolling BLA submission for U.S. accelerated approval for","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000171/0000875320-26-000171-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Q1 2026"},{"label":"Revenue","value":"$2.99 billion"},{"label":"Net income","value":"$1.0 billion"},{"label":"Result","value":"reported results"}]},{"claim_id":"8483c756fbeb30bb3def3937e27d2881462f837a","claim":"VERTEX PHARMACEUTICALS INC / MA reported FY 2026 results: revenue $12.95 billion to $13.1 billion. Guidance reaffirmed.","evidence_excerpt":"Vertex today reiterated full year 2026 financial guidance. Vertex's total revenue guidance of $12.95 billion to $13.1 billion","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000171/0000875320-26-000171-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"FY 2026"},{"label":"Revenue","value":"$12.95 billion to $13.1 billion"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"guidance update"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}